ArticleCurrent microbiology2026
Evaluation of a Novel Compound Probiotic Paste Containing Canine-Derived Vitamin B12-Producing Limosilactobacillus Reuteri.
Article in Current microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Chronic diarrhea in pets features high incidence, often causing vitamin B12 deficiency. Probiotics, which can alleviate or even treat chronic diarrhea by improving intestinal microbial balance, have shown promise. Previously, our laboratory isolated a strain of Limosilactobacillus reuteri (CLAB) with vitamin B12-producing capability from canine feces. However, it had suboptimal palatability and insufficient efficacy against chronic diarrhea and vitamin B12 deficiency. In this study, the CLAB was combined with Enterococcus faecalis and Saccharomyces cerevisiae to formulate a compound probiotic paste. The properties of the paste were comprehensively evaluated via a series of experiments including sensory evaluation, pH testing, microbial colony counting, palatability tests, disease activity index scoring, histopathological analysis, biochemical indicator analysis, and RNA quantification. The results demonstrated that the paste exhibited good stability, safety, and favorable palatability in both dogs and cats. Meanwhile, it significantly alleviated chronic diarrhea and vitamin B12 deficiency in mice. Specifically, the high-dose compound probiotic paste decreased myeloperoxidase and malondialdehyde levels in diarrheic mice from approximately 15.9 and 2.5 nmol/mgprot to about 4.2 and 1.7 nmol/mgprot; increased the total antioxidant capacity content and superoxide dismutase activity from approximately 0.5 nmol/mgprot and 1.0 U/mgprot to about 0.6 nmol/mgprot and 1.6 U/mgprot; and downregulated the relative mRNA levels of interleukin-6, interleukin-1β and tumor necrosis factor-α from approximately 2.1, 2.1 and 2.7 to about 1.2, 1.1 and 1.3, respectively. In conclusion, this study supports the potential use of the compound probiotic paste for preventing and treating chronic diarrhea and improving vitamin B12 deficiency in pets.
Indexed as
Identifiers
42709192What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.